Marketed marine natural products in the pharmaceutical and cosmeceutical industries: Tips for success

Marine Drugs

Volumn 12, Issue 2, 2014, Pages 1066-1101

  Martins, Ana ^a   Vieira, Helena ^a,b   Gaspar, Helena ^b   Santos, Susana ^b  

^a UNIVERSITY OF LISBON   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

Biodiscovery; Challenges; Cosmeceuticals; Marine natural products; Market; Pharmaceuticals; Success

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ANTINEOPLASTIC AGENT; ASG 5ME; BRENTUXIMAB VEDOTIN; CARRAGEENAN; CARRAGELOSE; COSMETIC; CYTARABINE; DEHYDRODIDEMNIN B; ELISIDEPSIN; ERIBULIN; EXOPOLYSACCHARIDE; GLEMBATUMUMAB VEDOTIN; KAHALALIDE F; LURBINECTEDIN; NATURAL PRODUCT; OMEGA 3 ACID ETHYL ESTER; OMEGA CONOTOXIN MVIIA; PLINABULIN; PM 00104; PM 060184; PRIAL; SALINOSPORAMIDE A; SOBLIDOTIN; SQUALAMINE; TALTOBULIN; TASIDOTIN; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE; VORSETUZUMAB MAFODOTIN; ZALYPSIS;

ALZHEIMER DISEASE; BIODIVERSITY; BREAST CANCER; COMBINATORIAL CHEMISTRY; COMMON COLD; CONTINUOUS INFUSION; COSMETIC INDUSTRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MECHANISM; DRUG SCREENING; DRUG STABILITY; ENVIRONMENTAL SUSTAINABILITY; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTRIGLYCERIDEMIA; LEUKEMIC MENINGITIS; MARINE ENVIRONMENT; MARINE SPECIES; MARKETING; NEUROPATHIC PAIN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SARCOMA;

ANIMALS; AQUATIC ORGANISMS; BIODIVERSITY; BIOLOGICAL PRODUCTS; COSMETICS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; INDUSTRY; MARKETING;

EID: 84896732066     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md12021066     Document Type: Review

References (128)

1. Mann, J.; Davidson, R.S.; Hobbs, J.B.; Banthorpe, D.V.; Harbourne, J.B. Natural Products, Their Chemistry and Biological Significance, 1st ed.; Longman Scientific and Technical Longman Group: London, UK, 1994.
2. Dias, D.A.; Urban, S.; Roessner, U. A historical overview of natural products in drug discovery. Metabolites 2012, 2, 303-336.
3. Carter, G.T. Natural products and Pharma 2011: Strategic changes spur new opportunities. Nat. Prod. Rep. 2011, 28, 1783-1789.
4. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311-335.
5. Margulis, L.; Schwartz, K.V. Five Kingdoms-An Illustrated Guide to the Phyla of Life on Earth, 3rd ed.; W.H. Freeman & Company: New York, NY, USA, 1998.
6. Gerwick, W.H.; Moore, B.S. Lessons from the past and charting the future of marine natural products drug discovery and chemical biology. Chem. Biol. 2012, 19, 85-98.
7. Leal, M.C.; Puga, J.; Serodio, J.; Gomes, N.C.M.; Calado, R. Trends in the discovery of new marine natural products from invertebrates over the last two decades - Where and what are we bioprospecting? PLoS One 2012, 7, e30580.
8. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2014, 31, 160-258.
9. Blunt, J.W.; Copp, B.R.; Keyzers, R.A.; Munro, M.H.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2013, 30, 237-323.
10. Bhatnagar, I.; Kim, S.K. Immense essence of excellence: Marine microbial bioactive compounds. Mar. Drugs 2010, 8, 2673-2701.
11. Waters, A.L.; Hill, R.T.; Place, A.R.; Hamann, M.T. The expanding role of marine microbes in pharmaceutical development. Curr. Opin. Biotechnol. 2010, 21, 780-786.
12. Penesyan, A.; Kjelleberg, S.; Egan, S. Development of novel drugs from marine surface associated microorganisms. Mar. Drugs 2010, 8, 438-459.
13. Piel, J. Metabolites from symbiotic bacteria. Nat. Prod. Rep. 2009, 26, 338-362.
14. Pettit, G.R.; Fujii, Y.; Hasler, J.A.; Schmidt, J.M. Isolation and characterization of palystatins A-D. J. Nat. Prod. 1982, 45, 272-276.
15. Berdy, J. Bioactive microbial metabolites. J. Antibiot. 2005, 58, 1-26.
16. Sudek, S.; Lopanik, N.B.; Waggoner, L.E.; Hildebrand, M.; Anderson, C.; Liu, H.; Patel, A.; Sherman, D.H.; Haygood, M.G. Identification of the putative bryostatin polyketide synthase gene cluster from "Candidatus Endobugula sertula", the uncultivated microbial symbiont of the marine bryozoan Bugula neritina. J. Nat. Prod. 2007, 70, 67-74.
17. Molinski, T.F.; Dalisay, D.S.; Lievens, S.L.; Saludes, J.P. Drug development from marine natural products. Nat. Rev. Drug Discov. 2009, 8, 69-85.
18. Schumacher, M.; Kelkel, M.; Dicato, M.; Diederich, M. Gold from the sea: Marine compounds as inhibitors of the hallmarks of cancer. Biotechnol. Adv. 2011, 29, 531-547.
19. Mishra, B.B.; Tiwari, V.K. Natural products: An evolving role in future drug discovery. Eur. J. Med. Chem. 2011, 46, 4769-4807.
20. Nelson, F.P.; Rumsfield, J. Cosmetics. Content and function. Int. J. Dermatol. 1988, 27, 665-672.
21. Marine Cosmeceuticals: Trends and Prospects; Kim, S.-K., Ed.; CRC Press, Taylor & Francis Group: Boca Raton, FL, USA, 2012.
22. Thomas, N.V.; Kim, S.-K. Beneficial effects of marine algal compounds in cosmeceuticals. Mar. Drugs 2013, 11, 146-164.
23. Raposo, M.F.; de Morais, R.M.; Bernardo de Morais, A.M. Bioactivity and applications of sulphated polysaccharides from marine microalgae. Mar. Drugs 2013, 11, 233-252.
24. Kim, Y.H.; Chung, C.B.; Kim, J.G.; Ko, K.I.; Park, S.H.; Kim, J.H.; Eom, S.Y.; Kim, Y.S.; Hwang, Y.I.; Kim, K.H. Anti-wrinkle activity of ziyuglycoside I isolated from a Sanguisorba officinalis root extract and its application as a cosmeceutical ingredient. Biosci. Biotechnol. Biochem. 2008, 72, 303-311.
25. Kijjoa, A.S. Pichan, drugs and cosmetics from the sea. Mar. Drugs 2004, 2, 73-74.
26. Imhoff, J.F.; Labes, A.; Wiese, J. Bio-mining the microbial treasures of the ocean: New natural products. Biotechnol. Adv. 2011, 29, 468-482.
27. Mayer, A.M.S.; Rodriguez, A.D.; Berlinck, R.G.S.; Hamann, M.T. Marine pharmacology in 2005-6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other miscellaneous mechanisms of action. Biochim. Biophys. Acta 2009, 1790, 283-308.
28. Ortholand, J.Y.; Ganesan, A. Natural products and combinatorial chemistry: Back to the future. Curr. Opin. Chem. Biol. 2004, 8, 271-280.
29. Beutler, J.A. Natural products as a foundation for drug discovery. Curr. Protoc. Pharmacol. 2009, 46, 9.11.1-9.11.21.
30. Radjasa, O.K.; Vaske, Y.M.; Navarro, G.; Vervoort, H.C.; Tenney, K.; Linington, R.G.; Crews, P. Highlights of marine invertebrate-derived biosynthetic products: Their biomedical potential and possible production by microbial associants. Bioorg. Med. Chem. 2011, 19, 6658-6674.
31. Glaser, K.B.; Mayer, A.M.S. A renaissance in marine pharmacology: From preclinical curiosity to clinical reality. Biochem. Pharmacol. 2009, 78, 440-448.
32. Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 2005, 4, 206-220.
33. Reynolds, W.F.; Enriquez, R.G. Choosing the best pulse sequences, acquisition parameters, postacquisition processing strategies, and probes for natural product structure elucidation by NMR spectroscopy. J. Nat. Prod. 2002, 65, 221-244.
34. Leeds, J.A.; Schmitt, E.K.; Krastel, P. Recent developments in antibacterial drug discovery: Microbe-derived natural products - From collection to the clinic. Expert Opin. Investig. Drugs 2006, 15, 211-226.
35. Brady, S.F. Construction of soil environmental DNA cosmid libraries and screening for clones that produce biologically active small molecules. Nat. Protoc. 2007, 2, 1297-1305.
36. Li, X.; Qin, L. Metagenomics-based drug discovery and marine microbial diversity. Trends Biotechnol. 2005, 23, 539-543.
37. Galm, U.; Shen, B. Natural product drug discovery: The times have never been better. Chem. Biol. 2007, 14, 1098-1104.
38. Zhang, W.; Dolan, M.E. Beyond the hapmap genotypic data: Prospects of deep resequencing projects. Curr. Bioinform. 2008, 3, 178; doi:10.2174/ 157489308785909232.
39. Piel, J. Combinatorial biosynthesis in symbiotic bacteria. Nat. Chem. Biol. 2006, 2, 661-662.
40. Mayer, A.M.S.; Glaser, K.B. Marine pharmacology and the marine pharmaceuticals pipeline. FASEB J. 2013, 27, 1167.7.
41. Newman, D.J.; Cragg, G.M. Marine natural products and related compounds in clinical and advanced preclinical trials. J. Nat. Prod. 2004, 67, 1216-1238.
42. Mayer, A.M.S.; Glaser, K.B.; Cuevas, C.; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; Newman, D.J.; Potts, B.C.; Shuster, D.E. The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol. Sci. 2010, 31, 255-265.
43. BCC Research. Available online: http://www.bccresearch.com/pressroom/phm/ global-market-marine-derived-drugs-reach-nearly-$8.6-billion-2016 (accessed on 25 November 2013).
44. Freedonia Group. Available online: http://www.freedoniagroup.com/ FreedoniaStudyIndex.aspx (accessed on 25 November 2013).
45. EurOcean. Available online: http://www.eurocean.org/np4/2502.html (acessed on 25 November 2013).
46. Rouhi, A.M. Supply Issues Complicate Trek of Chemicals from the Sea to Market. Chem. Eng. News 1995, 73, 42-44.
47. Leal, M.C.; Madeira, C.; Brandão, C.A.; Puga, J.; Calado, R. Bioprospecting of marine invertebrates for new natural products - A chemical and zoogeographical perspective. Molecules 2012, 17, 9842-9854.
48. Pettit, R.K. Culturability and secondary metabolite diversity of extreme microbes: Expanding contribution of deep sea and deep-sea vent microbes to natural product discovery. Mar. Biotechnol. 2011, 13, 1-11.
49. Montaser, R.; Luesch, H. Marine natural products: A new wave of drugs? Future Med. Chem. 2011, 3, 1475-1489.
50. Hill, R.T. Marine Natural Products Biotechnology. In Biotechnology; Volume 9. Available online: http://www.eolss.net/sample-chapters/c17/e6-58-08- 05.pdf (accessed on 25 November 2013).
51. Cragg, G.M.; Katz, F.; David, J.N.A.; Rosenthal, J. The impact of the United Nations Convention on Biological Diversity on natural products research. Nat. Prod. Rep. 2012, 29, 1407-1423.
52. Costello, M.J.; Bouchet, P.; Emblow, C.S.; Legakis, A. European marine biodiversity inventory and taxonomic resources: State of the art and gaps in knowledge. Mar. Ecol. Prog. Ser. 2006, 316, 257-268.
53. Jianga, X.; Xionga, J.; Songa, Z.; Morsed, J.C.; Jonese, F.C.; Xie, Z. Is coarse taxonomy sufficient for detecting macroinvertebrate patterns in floodplain lakes? Ecol. Indic. 2013, 27, 48-55.
54. Hughes, J.; Rees, S.; Kalindjian, S.; Philpott, K. Principles of early drug discovery. Br. J. Pharmacol. 2011, 162, 1239-1249.
55. Gribbon, P.; Sewing, A. High-throughput drug discovery: What can we exulect from HTS? Drug Discov. Today 2005, 10, 17-22.
56. Kingston, D.G.I. Modern natural products drug discovery and its relevance to biodiversity conservation. J. Nat. Prod. 2011, 74, 496-511.
57. Parker, C.N.; Ottl, J.; Gabriel, D.; Zhang, J.H. Advances in Biological Screening for Lead Discovery. In Natural Product Chemistry for Drug Discovery; Royal Society of Chemistry: Cambridge, UK, 2010.
58. Suyama, T.L.; Gerwick, W.H.; McPhail, K.L. Survey of marine natural product structure revisions: A synergy of spectroscopy and chemical synthesis. Bioorg. Med. Chem. 2011, 19, 6675-6701.
59. Maier, M.E. Structural revisions of natural products by total synthesis. Nat. Prod. Rep. 2009, 26, 1105-1124.
60. Michel, T.; Halabalaki, M.; Skaltsounis, A.L. New concepts, experimental approaches, and dereplication strategies for the discovery of novel phytoestrogens from natural sources. Planta Med. 2013, 79, 514-532.
61. AntiBase 2012, The Natural Compound Identifier. Available online: http://www.wiley-vch.de/stmdata/antibase.php (acessed on 20 November 2013).
62. MarinLit Database™, 2012, University of Canterbury, Christchurch, New Zealand. Available online: http://www.chem.canterbury.ac.nz/marinlit/ marinlit.shtml (accessed on 20 November 2013).
63. Dictionary of Natural Products Online™, A Subset of the Chapman & Hall/CRC CHEMICAL Database™. Available online: http://dnp. chemnetbase.com/dictionary-search.do?method=view&id=6930629&si= (accessed on 20 November 2013).
64. Lopez-Perez, J.L.; Theron, R.; del Olmo, E.; Diaz, D. NAPROC-13: A database for the dereplication of natural product mixtures in bioassay-guided protocols. Bioinformatics 2007, 23, 3256-3257.
65. Petersen, F.; Amstutz, R. Natural Compounds as Drugs; Birkhäuser: Basel, Switzerland, 2008.
66. Børresen, T.; Boyen, C.; Dobson, A.; Höfle, M.; Ianora, A.; Jaspars, M.; Kijjoa, A.; Olafsen, J.; Querellou, J.; Rigos, G.; et al. Marine Biotechnology: A New Vision and Strategy for Europe. Marine Board-ESF Position Paper 15. Available online: http://www.marine.ie/NR/rdonlyres/C076682C-2B32- 437C-A781-B2EACBAA6B62/0/ESFMBmarine-biotechnology-paper15LR.pdf (accessed on 27 January 2014).
67. Meyer, C.A. The Global Marine Pharmaceuticals Pipeline. Available online: http://marinepharmacology.midwestern.edu/ (accessed on 8 November 2013).
68. Schuster, D.; Laggner, C.; Langer, T. Why drugs fail - A study on side effects in new chemical entities. Curr. Pharm. Des. 2005, 11, 3545-3559.
69. Lichtman, M.A. A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7 + 3. Blood Cells Mol. Dis. 2013, 50, 119-130.
70. Cimino, G.; Derosa, S.; Destefano, S. Antiviral agents from a gorgonian, eunicella-cavolini. Experientia 1984, 40, 339-340.
71. Chhikara, B.S.; Parang, K. Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opin. Drug Deliv. 2010, 7, 1399-1414.
72. Kripp, M.; Hofheinz, R.D. Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine. Int. J. Nanomed. 2008, 3, 397-401.
73. National Cancer Institute, Clinical Trials (PDQ®). Available online: http://www.cancer.gov/clinicaltrials/search/results?protocolsearchid=6532271 (accessed on 1 November 2013).
74. Clavis Pharma Announces Negative Outcome of Phase III CLAVELA Trial with Elacytarabine in Patients with Acute Myeloid Leukaemia. Available online: http://aqualis.no/home (accessed on 1 November 2013).
75. Shen, W.; Kim, J.S.; Kish, P.E.; Zhang, J.; Mitchell, S.; Gentry, B.G.; Breitenbach, J.M.; Drach, J.C.; Hilfinger, J. Design and synthesis of vidarabine prodrugs as antiviral agents. Bioorg. Med. Chem. Lett. 2009, 19, 792-796.
76. Lloyd-Evans, L.P.M. A Study into the Prospects for Marine Biotechnology Development in the United Kingdom. Foresight Marine Panel, Marine Biotechnology Group 2005. Available online: http://www.vliz.be/imisdocs/publications/238815. pdf (accessed on 25 November 2013).
77. Mcintosh, M.; Cruz, L.J.; Hunkapiller, M.W.; Gray, W.R.; Olivera, B.M. Isolation and structure of a peptide toxin from the marine snail conus-magus. Arch. Biochem. Biophys. 1982, 218, 329-334.
78. Oliveira, B.M. ω-Conotoxin MVIIA: From Marine Snail Venom to Analgesic Drug. In Drugs from the Sea; Karger: Basel, Switzerland; New York, NY, USA, 2000.
79. Bauer, A.; Bronstrup, M. Industrial natural product chemistry for drug discovery and development. Nat. Prod. Rep. 2013, 31, 35-60.
80. Schmidtko, A.; Lotsch, J.; Freynhagen, R.; Geisslinger, G. Ziconotide for treatment of severe chronic pain. Lancet 2010, 375, 1569-1577.
81. Elan 2010 Annual Report; Elan Corporation: Dublin, Ireland, 2010.
82. Olivera, B.M. Conus peptides: Biodiversity-based discovery and exogenomics. J. Biol. Chem. 2006, 281, 31173-31177.
83. Vemomics for Health. Available online: http://www.venomics.eu/ (accessed on 1 November 2013).
84. Glueck, C.J.; Khan, N.; Riaz, M.; Padda, J.; Khan, Z.; Wang, P. Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dL despite conventional triglyceride lowering therapy. Lipids Health Dis. 2012, 11, 143.
85. A® (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Adv. Ther. 2009, 26, 675-690.
86. Koski, R.R. Omega-3-acid ethyl esters (lovaza) for severe hypertriglyceridemia. Pharm. Ter. 2008, 33, 271-303.
87. D'Incalci, M.; Galmarini, C.M. A review of trabectedin (ET-743): A unique mechanism of action. Mol. Cancer Ther. 2010, 9, 2157-2163.
88. Monk, B.J.; Dalton, H.; Benjamin, I.; Tanovic, A. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr. Pharm. Des. 2012, 18, 3754-3769.
89. Cuevas, C.; Francesch, A. Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat. Prod. Rep. 2009, 26, 322-337.
90. PharmaMar. Annual report 2011. Available online: http://www.pharmamar. com/pdf/EN-memoria2012.pdf (accessed on 25 November 2013).
91. Aicher, T.D.; Buszek, K.R.; Fang, F.G.; Forsyth, C.J.; Jung, S.H.; Kishi, Y.; Matelich, M.C.; Scola, P.M.; Spero, D.M.; Yoon, S.K. Total synthesis of halichondrin-B and norhalichondrin-B. J. Am. Chem. Soc. 1992, 114, 3162-3164.
92. Towle, M.J.; Salvato, K.A.; Budrow, J.; Wels, B.F.; Kuznetsov, G.; Aalfs, K.K.; Welsh, S.; Zheng, W.J.; Seletsky, B.M.; Palme, M.H.; et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001, 61, 1013-1021.
93. NCI. Development Therapeutics Program, Success storY: Halichondrin B (NSC 609395) E7389 (NSC 707389). Available online: http://dtp.nci.nih.gov/timeline/ flash/success-stories/S4-halichondrinB.htm (accessed on 3 November 2013).
94. Pettit, G.R.; Kamano, Y.; Herald, C.L.; Tuinman, A.A.; Boettner, F.E.; Kizu, H.; Schmidt, J.M.; Baczynskyj, L.; Tomer, K.B.; Bontems, R.J. Antineoplastic agents 136. The isolation and structure of a remarkable marine animal antineoplastic constituent - Dolastatin 10. J. Am. Chem. Soc. 1987, 109, 6883-6885.
95. Eccles, R.; Meier, C.; Jawad, M.; Weinmullner, R.; Grassauer, A.; Prieschl-Grassauer, E. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: A randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir. Res. 2010, 11, 108.
96. Euromonitor. Available online: http://www.euromonitor.com/skin-care (accessed on 25 November 2013).
97. Chi, Z.; Fang, Y. Exopolysaccharides from marine bacteria. J. Ocean Univ. China 2005, 4, 67-74.
98. Nichols, C.A.; Guezennec, J.; Bowman, J.P. Bacterial exopolysaccharides from extreme marine environments with special consideration of the southern ocean, sea ice, and deep-sea hydrothermal vents: A review. Mar. Biotechnol. 2005, 7, 253-271.
99. Vincent, P.; Pignet, P.; Talmont, F.; Bozzi, L.; Fournet, B.; Guezennec, J.; Jeanthon, C.; Prieur, D. Production and characterization of an exopolysaccharide excreted by a deep-sea hydrothermal vent bacterium isolated from the polychaete annelid alvinella pompejana. Appl. Environ. Microbiol. 1994, 60, 4134-4141.
100. Raguenes, G.; Pignet, P.; Gauthier, G.; Peres, A.; Christen, R.; Rougeaux, H.; Barbier, G.; Guezennec, J. Description of a new polymer-secreting bacterium from a deep-sea hydrothermal vent, Alteromonas macleodii subsp. fijiensis, and preliminary characterization of the polymer. Appl. Environ. Microbiol. 1996, 62, 67-73.
101. Raguenes, G.; Christen, R.; Guezennec, J.; Pignet, P.; Barbier, G. Vibrio diabolicus sp. nov., a new polysaccharide-secreting organism isolated from a deep-sea hydrothermal vent polychaete annelid, Alvinella pompejana. Int. J. Syst. Bacteriol. 1997, 47, 989-995.
102. Raguenes, G.H.; Peres, A.; Ruimy, R.; Pignet, P.; Christen, R.; Loaec, M.; Rougeaux, H.; Barbier, G.; Guezennec, J.G. Alteromonas infernus sp. nov., a new polysaccharide-producing bacterium isolated from a deep-sea hydrothermal vent. J. Appl. Microbiol. 1997, 82, 422-430.
103. Rougeaux, H.; Guezennec, J.; Carlson, R.W.; Kervarec, N.; Pichon, R.; Talaga, P. Structural determination of the exopolysaccharide of Pseudoalteromonas strain HYD 721 isolated from a deep-sea hydrothermal vent. Carbohydr. Res. 1999, 315, 273-285.
104. Cambon-Bonavita, M.A.; Raguenes, G.; Jean, J.; Vincent, P.; Guezennec, J. A novel polymer produced by a bacterium isolated from a deep-sea hydrothermal vent polychaete annelid. J. Appl. Microbiol. 2002, 93, 310-315.
105. Weiner, R.; Langille, S.; Quintero, E. Structure, function and immunochemistry of bacterial exopolysaccharides. J. Ind. Microbiol. 1995, 15, 339-346.
106. Desbruyeres, D.; Laubier, L. Alvinella pompejana gen. sp. nov., aberrant Ampharetidae from East Pacific Rise hydrothermal vents. Oceanol. Acta 1980, 3, 326-274.
107. Le Costaouëc, T.; Cérantola, S.; Ropartz, D.; Sinquin, C.; Colliec-Jouault, S.; Boisset, C. Structural data on a bacterial exopolysaccharide produced by a deep-sea Alteromonas macleodii strain. Carbohydr. Polym. 2012, 90, 49-59.
108. Thibodeau, A.; Takeoka, A. The applications and functions of new exopolysaccharide "Deepsane" from the deepest oceans. Fragr. J. 2006, 34, 61-68.
109. Potts, B.C.; Faulkner, D.J.; Jacobs, R.S. Phospholipase A2 inhibitors from marine organisms. J. Nat. Prod. 1992, 55, 1701-1717.
110. Day, D.R.; Jabaiah, S.; Jacobs, R.S.; Little, R.D. Cyclodextrin formulation of the marine natural product pseudopterosin A uncovers optimal pharmacodynamics in proliferation studies of human umbilical vein endothelial cells. Mar. Drugs 2013, 11, 3258-3271.
111. Rouhi, A.M. Betting on natural products for cures. Chem. Eng. News 2003, 81, 93-103.
112. Lipotec. Available online: http://www.lipotec.com (accessed on 25 November 2013).
113. Ivatt, R.J. The Biology of Glycoproteins; Plenum Press: New York, NY, USA, 1984.
114. Gottschalk, A. Glycoproteins: Their Composition, Structure and Function; Elsevier Publishing Company: New York, NY, USA, 1972.
115. Martins, A.; Tenreiro, T.; Andrade, G.; Gadanho, M.; Chaves, S.; Abrantes, M.; Calado, P.; Tenreiro, R.; Vieira, H. Photoprotective bioactivity present in a unique marine bacteria collection from Portuguese deep sea hydrothermal vents. Mar. Drugs 2013, 11, 1506-1523.
116. RefirMAR™ by BIOALVO. Available online: http://www.bioalvo.com/ products/products-bioactive-ingredients/refirmar (accessed on 1 November 2013).
117. Satyanarayana, K.G.; Mariano, A.B.; Vargas, J.V.C. A review on microalgae, a versatile source for sustainable energy and materials. Int. J. Energy Res. 2011, 35, 291-311.
118. Stolz, P.; Obermayer, B. Manufacturing microalgae for skin care. Cosmet. Toilet. 2005, 120, 99-106.
119. CODIF Website. Available online: http://www.codif-recherche-et nature.com/en/s06-catalogue/s06p02-fiche.php?prod=56 (accessed on 25 November 2013).
120. An Unlimite Mine of Innovation. Available online: http://greensea.fr/en/ active-ingredients (accessed on 25 November 2013).
121. Patented Breakthrough Ingredient. Available online: http://www.algenist. com/why-algenist/patented-breakthrough-ingredient (accessed on 25 November 2013).
122. Frutarom. Available online: http://www.frutarom.com/FrutaromNew/index.asp (accessed on 25 November 2013).
123. Senaratne, L.S.; Park, P.J.; Kim, S.K. Isolation and characterization of collagen from brown backed toadfish (Lagocephalus gloveri) skin. Bioresour. Technol. 2006, 97, 191-197.
124. Alan, H. Strategies for discovering drugs from previously unexplored natural products. Drug Discov. Today 2000, 5, 294-300.
125. Wagenaar, M.M. Pre-fractionated microbial samples-The second generation natural products library at Wyeth. Molecules 2008, 13, 1406-1426.
126. Cobb, R.E.; Ning, J.C.; Zhao, H. DNA assembly techniques for next generation combinatorial biosynthesis of natural products. J. Ind. Microbiol. Biotechnol. 2014, 41, 469-477.
127. Pollier, J.; Moses, T.; Goossens, A. Combinatorial biosynthesis in plants: A (p)review on its potential and future exploitation. Nat. Prod. Rep. 2011, 28, 1897-1916.
128. Leal, M.C.; Calado, R.; Sheridan, C.; Alimonti, A.; Osinga, R. Coral aquaculture to support drug discovery. Trends Biotechnol. 2013, 31, 555-561.